Pharmaceuticals for Women's Health: Global Markets to 2023

  • ID: 4587233
  • Report
  • Region: Global
  • 141 pages
  • BCC Research
1 of 5

FEATURED COMPANIES

  • Abbvie Inc.
  • Allergan Plc.
  • Amgen Inc.
  • Bayer Ag
  • Eli Lilly And Company
  • Johnson & Johnson Inc.
  • MORE
Report Scope:

While women’s health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders. This report does not focus on drugs for infertility, diagnostic and drug technologies for breast cancer or therapies and diagnostics for ovarian cancer. However, we have individuals reports which discusses the scope of these health concerns in detail. The report codes for these reports are listed below:
  • PHM194A Drugs for Infertility: Global Markets.
  • HLC143B Therapies and Diagnostics for Ovarian Cancer: Global Markets.
  • HLC209A U.S. Fertility Clinics Market.
  • HLC106B Breast Cancer Diagnostic and Drug Technologies: Global Markets.
Report Includes:
  • 26 data tables and 34 additional tables
  • Detailed overview of the global markets for pharmaceuticals for women's health
  • Country specific data and analysis for United States, Mexico, Germany, U.K., France, China, India, Japan, Middle East and Africa
  • A look at the regulatory environment which has been a driving force in the drug development industry
  • Information on competitor initiatives, and information with regard to demand for specialty chemicals used to develop new products and for new applications
  • A relevant patent analysis within the sector
  • Comprehensive company profiles of major Players in the Market including AbbVie Inc., Allergan PLC, Amgen Inc., Bayer Ag., Eli Lilly and Company, Johnson & Johnson Inc., Novo Nordisk and Pfizer Inc.
Membership Price:

Contact us for membership pricing.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie Inc.
  • Allergan Plc.
  • Amgen Inc.
  • Bayer Ag
  • Eli Lilly And Company
  • Johnson & Johnson Inc.
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Technologies and Global Markets Overview

  • Disease Overview and Definitions
  • Market Driving Factors and Opportunities
  • Aging Female Population
  • Government Involvement and Increased Funding
  • Increasing Awareness Regarding Women's Disorders and Treatments
  • Market Restraints
  • Poor Diagnosis
  • Availability of Alternate Treatment Options and Lifestyle Changes
  • Unavailability of Novel Treatments
  • High Cost of Treatment

Chapter 4 Pipeline Assessment and Analysis

  • List of Drugs in Pipeline
  • Overview of Osteoporosis Drug Development Pipeline
  • Late-stage Pipeline Drugs
  • Elagolix (AbbVie Inc.)
  • Vilaprisan (Bayer AG)
  • Evenity (Amgen Inc.)
  • Relugolix (Myovant Sciences)
  • Proellex (Repros Therapeutics)
  • Esmya (Allergan Inc.)
  • TX-004HR (TherapeuticsMD, Inc.)
  • TX-001HR (TherapeuticsMD, Inc.)

Chapter 5 Regulatory Structure

  • Overview of Regulations
  • United States
  • Canada
  • Europe
  • Japan
  • Overview of Pricing and Reimbursement
  • United States
  • Canada
  • Europe
  • Japan

Chapter 6 Market Breakdown by Women's Health Disorders

  • Introduction
  • Menopause-Related Diseases
  • Overview
  • Symptoms
  • Risk Factors
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Postmenopausal Osteoporosis
  • Overview
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Endometriosis
  • Overview
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Polycystic Ovary Syndrome (PCOS)
  • Overview
  • Reducing the Risk of PCOS
  • Epidemiology and Economic Burden
  • Diagnosis
  • Treatments
  • Market Size and Forecasts
  • Pregnancy Disorders and Management
  • Overview
  • Market Size and Forecasts
  • Others
  • Overview
  • Market Size and Forecasts

Chapter 7 Market Breakdown by Region

  • Introduction
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
  • South America
  • Middle East and Africa

Chapter 8 Competitive Landscape and Key Developments

  • Market Players and Strategy
  • Patent Analysis
  • List of Key Patents
  • Key Developments
  • Mergers and Acquisitions
  • Development of Innovative Products/Novel Product Launch
  • Agreements, Collaborations & Partnerships
  • Key Products

Chapter 9 Company Profiles

  • ABBVIE INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • ALLERGAN PLC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • AMGEN INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • BAYER AG
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • DAIICHI SANKYO COMPANY. LTD.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • ELI LILLY AND COMPANY
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • JOHNSON & JOHNSON INC.
  • Company Overview
  • Product Information
  • Financials
  • MERCK & CO. INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials
  • MERCK KGAA
  • Company Overview
  • Product Information
  • NOVO NORDISK
  • Company Overview
  • Product Information
  • Financials
  • PFIZER INC.
  • Company Overview
  • Product Information
  • Development and Strategies
  • Financials

Chapter 10 Appendix

  • Abbreviations Used in the Report

List of Tables
Summary Table: Global Market for Women's Health Therapeutics, by Disease Area, Through 2023
Table 1: Life Expectancy at Birth, Both Sexes Combined, by Region
Table 2: Pipeline Molecules, Endometriosis
Table 3: Pipeline Molecules, Uterine Fibroids
Table 4: Pipeline Molecules, All Other Indications
Table 5: Pipeline Molecules, Osteoporosis
Table 6: Elagolix Snapshot
Table 7: Vilaprisan Snapshot
Table 8: Evenity Snapshot
Table 9: Relugolix Snapshot
Table 10: Proellex Snapshot
Table 11: Esmya Snapshot
Table 12: TX-004HR Snapshot
Table 13: TX-001HR Snapshot
Table 14: Global Market for Women’s Health Therapeutics, by Disease Area, Through 2023
Table 15: FDA Approved Estrogen-only Medicines
Table 16: FDA Approved Progestin-only Medicines
Table 17: FDA Approved Combination, Estrogen and Progestin Medicines
Table 18: FDA Approved Combination Estrogen and Hormone Medicines
Table 19: Vagifem (10mcg), Patent Expiration
Table 20: Global Menopause Market, by Region, Through 2023
Table 21: Prolia/XGEVA (Denosumab) Patent Expiration
Table 22: Global Postmenopausal Osteoporosis Market, by Region, Through 2023
Table 23: Global Endometriosis Market, by Region, Through 2023
Table 24: Global Polycystic Ovary Syndrome Market, by Region, Through 2023
Table 25: Global Pregnancy Disorders and Management Market, by Region, Through 2023
Table 26: Global Women’s Health Therapeutics Others Market, by Region, Through 2023
Table 27: Global Women’s Health Therapeutics, by Region, Through 2023
Table 28: North American Market for Women’s Health Therapeutics, by Disease Area Through 2023
Table 29: European Market for Women’s Health Therapeutics, by Disease Area, Through 2023
Table 30: Asia Pacific Market for Women’s Health Therapeutics, by Disease Area, Through 2023
Table 31: South America Market for Women’s Health Therapeutics, by Disease Area, Through 2023
Table 32: Middle East and Africa Market for Women’s Health Therapeutics, by Disease Area, Through 2023
Table 33: Company Share Analysis, by Indication, 2017
Table 34: Tier III Companies
Table 35: Patent Review
Table 36: Marketed Products, Postmenopausal Osteoporosis
Table 37: AbbVie Inc., Marketed Products
Table 38: AbbVie Inc., Net Revenue, 2015-2017
Table 39: Allergan Plc., Marketed Products
Table 40: Allergan Plc., Net Revenue, 2015-2017
Table 41: Amgen Inc., Marketed Products, 2016
Table 42: Amgen Inc.: Net Revenue, 2015-2017
Table 43: Bayer AG, Marketed Products
Table 44: Bayer AG, Net Revenue, 2015-2017
Table 45: Daiichi Sankyo Company. Ltd., Marketed Products
Table 46: Daiichi Sankyo Company Ltd. Net Revenue 2015-2017
Table 47: Eli Lilly and Company, Marketed Products
Table 48: Eli Lilly and Company Net Revenue, 2015-2017
Table 49: Johnson & Johnson Inc., Marketed Products, 2016
Table 50: Johnson & Johnson Inc. Net Revenue, 2014-2016
Table 51: Merck & Co. Inc. Marketed Products
Table 52: Merck & Co. Inc. Net Revenue, 2014-2016
Table 53: Merck KGaA Marketed Products
Table 54: Novo Nordisk, Marketed Products
Table 55: Novo Nordisk, Net Revenue, 2015-2017
Table 56: Pfizer Inc. Marketed Products by Indication, 2016
Table 57: Pfizer Inc. Net Revenue, 2014-2016
Table 58: Glossary of Terms Used in Women’s Health Therapeutics
Table 59: Abbreviations Used in Women’s Health Therapeutics

List of Figures
Summary Figure: Global Market for Women’s Health Therapeutics, by Disease Area, 2017-2023
Figure 1: Older Population Distribution, by Age Group and Sex, 2017
Figure 2: Older Population Distribution, by Age Group and Sex, 2050
Figure 3: Funding for Research, Disease Condition/Category, 2014-2016
Figure 4: Funding for Research, Women’s Health, 2014-2016
Figure 5: Insurance Coverage in the U.S., by Healthcare Providers, 2014
Figure 6: Global Women's Health Therapeutics Market, 2017-2023
Figure 7: Global Women's Health Therapeutics Market Share, by Disease Area, 2018
Figure 8: Global Women's Health Therapeutics Market Share, by Disease Area, 2023
Figure 9: Global Menopause Market, 2017-2023
Figure 10: Global Menopause Market, by Region, 2017-2023
Figure 11: Australia Rate of Hospitalization for Osteoporosis, People Aged 50 and Over, 2015-2016
Figure 12: Global Postmenopausal Osteoporosis Market, 2017-2023
Figure 13: Global Postmenopausal Osteoporosis Market, by Region, 2017-2023
Figure 14: Global Endometriosis Market, 2017-2023
Figure 15: Global Endometriosis Market, by Region, 2017-2023
Figure 16: Global Polycystic Ovary Syndrome Market, 2017-2023
Figure 17: Global Polycystic Ovary Syndrome Market, by Region, 2017-2023
Figure 18: Global Pregnancy Disorders and Management Market, 2017-2023
Figure 19: Global Pregnancy Disorders and Management Market, by Region, 2017-2023
Figure 20: Global Women’s Health Therapeutics Market for Others, 2017-2023
Figure 21: Global Women’s Health Therapeutics Others Market, 2017-2023
Figure 22: Global Women’s Health Therapeutics Market, by Region, 2017-2023
Figure 23: North America Women's Health Therapeutics Market, 2017-2023
Figure 24: North America Women's Health Therapeutics Market Share, by Disease Area, 2018
Figure 25: North America Women's Health Therapeutics Market Share, by Disease Area, 2023
Figure 26: North America Market for Women's Health Therapeutics, by Country, 2017-2023
Figure 27: United States Women’s Health Therapeutics Market, 2017- 2023
Figure 28: Canada Women's Health Therapeutics Market, 2017-2023 ($ Millions)
Figure 29: Mexico Women’s Health Therapeutics Market, 2017-2023
Figure 30: Europe Women’s Health Therapeutics Market, 2017-2023
Figure 31: Europe Women's Health Therapeutics Market Share, by Disease Area, 2018
Figure 32: Europe Women's Health Therapeutics Market Share, by Disease Area, 2023
Figure 33: Europe Market for Women's Health Therapeutics, by Country, 2017-2023
Figure 34: United Kingdom Women's Health Therapeutics Market, 2017-2023
Figure 35: Germany Women's Health Therapeutics Market, 2017-2023
Figure 36: France Women's Health Therapeutics Market, 2017-2023
Figure 37: Spain Women's Health Therapeutics Market, 2017-2023
Figure 38: Italy Women's Health Therapeutics Market, 2017-2023
Figure 39: Rest of Europe Women's Health Therapeutics Market, 2017-2023
Figure 40: Asia-Pacific Women's Health Therapeutics Market, 2017-2023
Figure 41: Asia-Pacific Women's Health Therapeutics Market Share, by Disease Area, 2018
Figure 42: Asia-Pacific Women's Health Therapeutics Market Share, by Disease Area, 2023
Figure 43: Asia Pacific Market for Women's Health Therapeutics, by Country, 2017-2023
Figure 44: China Women's Health Therapeutics Market, 2017-2023
Figure 45: Japan Women's Health Therapeutics Market, 2017-2023
Figure 46: India Women's Health Therapeutics Market, 2017-2023
Figure 47: South Korea Women's Health Therapeutics Market, 2017-2023
Figure 48: Asia-Pacific Women's Health Therapeutics Market, 2017-2023
Figure 49: South America Women's Health Therapeutics Market, 2017-2023
Figure 50: South America Women's Health Therapeutics Market Share, by Disease Area, 2018
Figure 51: South America Women's Health Therapeutics Market Share, by Disease Area, 2023
Figure 52: Middle East & Africa Women's Health Therapeutics Market, 2017-2023
Figure 53: Middle East & Africa Women's Health Therapeutics Market Share, by Disease Area, 2018
Figure 54: Middle East & Africa Women's Health Therapeutics Market Share, by Disease Area, 2023
Figure 55: Global Women's Health Therapeutics Market Share Analysis, 2017
Figure 56: AbbVie Inc., Revenue Share, by Region, 2016
Figure 57: Allergan PLC., Revenue Share, by Business Segment, 2016
Figure 58: Amgen Inc. R&D Expenditure, 2014-2016
Figure 59: Amgen Inc.: Revenue Share, by Region, 2017
Figure 60: Bayer AG, Revenue Share, by Region, 2017
Figure 61: Bayer AG, Revenue Share, by Business Segment, 2017
Figure 62: Daiichi Sankyo Company. Ltd., R&D Expenditure, 2014-2016
Figure 63: Daiichi Sankyo Company Revenue Share by Business Segment, 2016
Figure 64: Eli Lilly and Company Revenue Share by Business Segment, 2016
Figure 65: Eli Lilly and Company Revenue Share by Region, 2016
Figure 66: Johnson and Johnson Inc. Revenue Share, by Business Segment, 2016
Figure 67: Johnson and Johnson Inc. Revenue Share, by Region, 2016
Figure 68: Merck & Co. Inc. Revenue Share by Business Segment, 2016
Figure 69: Merck & Co. Inc. Revenue Share by Region, 2016
Figure 70: Novo Nordisk, Revenue Share, by Region, 2016
Figure 71: Novo Nordisk, Revenue Share, by Business Segment, 2016
Figure 72: Pfizer Inc. Revenue Share, by Region, 2016
Figure 73: Pfizer Inc. Revenue Share, by Business Segment, 2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbvie Inc.
  • Allergan Plc.
  • Amgen Inc.
  • Bayer Ag
  • Daiichi Sankyo Company. Ltd.
  • Eli Lilly And Company
  • Johnson & Johnson Inc.
  • Merck & Co. Inc.
  • Merck Kgaa
  • Novo Nordisk
  • Pfizer Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll